Quality Assurance in Prostate Biopsy Sampling, Processing, and Reporting: A New Pathologic Paradigm for Prostate Cancer Diagnosis

2012 ◽  
pp. 141-151
Author(s):  
David G. Bostwick
Keyword(s):  
Prostate Cancer ◽  
Quality Assurance ◽  
Cancer Diagnosis ◽  
Prostate Biopsy ◽  
Prostate Cancer Diagnosis

scholarly journals Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jaegeun Lee ◽  
Seung Woo Yang ◽  
Long Jin ◽  
Chung Lyul Lee ◽  
Ji Yong Lee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Prostate Biopsy ◽  
Peripheral Zone ◽  
Transitional Zone ◽  
Gray Zone ◽  
Prostate Cancer Diagnosis ◽  
Psa Density ◽  
Diagnosis Group ◽  
Predictive Rate

Abstract Background Serum prostate-specific antigen (PSA) is widely used in screening tests for prostate cancer. As the low specificity of PSA results in unnecessary and invasive prostate biopsies, we evaluated the clinical significance of various PSAs and PSA density (PSAD) related to peripheral zones in patients with gray zone PSA level (4–10 ng/mL). Methods A total of 1300 patients underwent transrectal ultrasonography-guided prostate biopsy from 2014 to 2019. Among them, 545 patients in the gray zone were divided into the prostate cancer diagnosis group and the non-prostate cancer diagnosis group, and PSA, relative extra transitional zone PSA (RETzPSA), estimated post holmium laser enucleation of the prostate PSA (EPHPSA), PSAD, peripheral zone PSA density (PZPSAD) and extra-transitional zone density (ETzD) were compared and analyzed using receiver-operating characteristics (ROC) analysis after 1:1 matching using propensity score. Results Area under the ROC curve values of PSA, EPHPSA, RETzPSA, PSA density, ETzD, and PZPSAD were 0.553 (95% CI: 0.495–0.610), 0.611 (95% CI: 0.554–0.666), 0.673 (95% CI: 0.617–0.725), 0.745 (95% CI: 0.693–0.793), 0.731 (95% CI: 0.677–0.780) and 0.677 (95% CI: 0.611–0.719), respectively. PSAD had 67.11% sensitivity, 71.71% specificity, and 70.34% positive predictive rate at 0.18 ng/mL/cc. ETzD had 69.08% sensitivity, 64.47% specificity, and 66.04% positive predictive rate at 0.04 ng/mL/cc. When the cut-off value of PSAD was increased to 0.18 ng/mL/cc, the best results were obtained with an odds ratio of 5.171 (95% CI: 3.171–8.432), followed by ETzD with 4.054 (95% CI: 2.513–6.540). Conclusions These results suggested that volume-adjusted parameters (ETzD and PSAD) might be more sensitive and accurate than various PSA in gray zone patients who required prostate biopsy to reduce unnecessary biopsy.

NOMOGRAM TO PREDICT PROSTATE CANCER DIAGNOSIS ON TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY IN A CONTEMPORARY SERIES

2008 ◽  
Vol 179 (4S) ◽  
pp. 643-644
Author(s):  
Christopher J DiBlasio ◽  
Michael M Maddox ◽  
Reza Mehrazin ◽  
John B Malcolm ◽  
Michael A Aleman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Prostate Biopsy ◽  
Transrectal Ultrasound ◽  
Ultrasound Guided ◽  
Prostate Cancer Diagnosis

scholarly journals MP13-06 MULTICENTER CLINICAL TRIAL OF REAL-TIME PROSTATE CANCER DIAGNOSIS USING OPTICAL SPECTROSCOPY GUIDED PROSTATE BIOPSY

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
James Wysock* ◽  
Neal Shore ◽  
Michael Gorin ◽  
Alan Partin ◽  
Behfar Ehdaie ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Real Time ◽  
Optical Spectroscopy ◽  
Cancer Diagnosis ◽  
Prostate Biopsy ◽  
Multicenter Clinical Trial ◽  
Prostate Cancer Diagnosis

scholarly journals The Role of the Serum 25-OH Vitamin D Level in Detecting Prostate Cancer in Men with Elevated Prostate-Specific Antigen Levels

2022 ◽  
Author(s):  
Min Hyuk Kim ◽  
Sangjun Yoo ◽  
Min Soo Choo ◽  
Min Chul Cho ◽  
Hwancheol Son ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Cancer Diagnosis ◽  
Prostate Biopsy ◽  
Serum Vitamin ◽  
Study Cohort ◽  
Prostate Cancer Diagnosis ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Clinically Significant

Abstract We aimed to determine whether vitamin D levels before prostate biopsy have diagnostic value for clinically significant prostate cancer. The study cohort included patients who underwent prostate biopsy. A total of 224 patients were enrolled in our study, and serum vitamin D levels were measured from February 2016 to December 2019 in routine laboratory tests. To determine the relationship between vitamin D levels and the aggressiveness of prostate cancer, we used multivariate analysis. Based on the histopathological results, the serum vitamin D level was marginally lower in the group with higher positive cores and pT3 or higher, and the serum vitamin D level was significantly lower in the large tumor volume group. In the univariate analysis, the prostate cancer diagnosis rate was associated with low vitamin D levels. In clinically significant prostate cancer diagnosis, low vitamin D levels were found in the univariate (odds ratio [OR], 0.955; P<0.001) and multivariate (OR, 0.944; P=0.027) analyses. In conclusion, we found that the incidence of prostate cancer tends to increase as the vitamin D level is lower in the Asian population, and this is particularly helpful in diagnosing clinically significant prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document